Loading
Latest filing published 14 May 2026 for Indivior Pharmaceuticals, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Mark Stejbach is a declared insider at 3 companies (board member); the most frequent names are Flexion Therapeutics Inc, Indivior Pharmaceuticals, Inc. and Indivior PLC. The record holds 5 filings, for trades running from 24 June 2021 to 13 May 2026.
On the market, this insider has only ever bought: 1 purchase, €23k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 3 share grants. 2026 to date brings 1 purchase and no sales.
The latest filing, published on 14 May 2026, reports a share grant in Indivior Pharmaceuticals, Inc. The most recent open-market purchase was published on 7 January 2026, 284 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations